Ibrilatazar is under clinical development by Ability Pharmaceuticals and currently in Phase III for Metastatic Pancreatic Cancer.

Department of Molecular, Cell and Systems Biology, University of California Riverside, Riverside, USA Stowers Institute for Medical Research, Kansas City, USA ...